Target intelligence / Profile preview

Positively charged proteins in damaged mucosa

Molecular classification
Other
01

Overview

Positively charged proteins in damaged mucosa represent a physiological target for cytoprotective agents used in the treatment of acid-peptic disorders (StatPearls, 2023). In conditions such as peptic ulcer disease or erosive gastritis, the protective epithelial layer is breached, exposing underlying proteins like albumin and fibrinogen that carry a net positive charge in the acidic environment of the stomach (PubChem). These proteins serve as an electrostatic anchor for polyanionic drugs like sucralfate, which polymerize into a sticky, gel-like substance (Goodman & Gilman, 2018). This interaction forms a physical barrier over the ulcerated area, shielding the sensitive tissue from aggressive factors including hydrochloric acid, pepsin, and bile acids. By isolating the damaged site, this mechanism facilitates the natural healing process and prevents further erosion of the mucosal lining. While not a single receptor, this collection of proteins is a critical pharmacological target for localized, non-systemic therapy in gastroenterology.

Other names
Exposed proteins in ulcerated mucosaNecrotic tissue proteinsUlcer base proteinsAlbumin and fibrinogen in damaged mucosa
02

Mechanism of action

Sucralfate undergoes polymerization in an acidic environment (pH < 4) to form a viscous, negatively charged paste that electrostatically binds to positively charged proteins (such as albumin and fibrinogen) exposed in the damaged mucosa or ulcer base (StatPearls, 2023).

03

Biological functions

Other
04

Disease associations

InflammationOther
05

Safety considerations

Aluminum accumulation in patients with chronic renal failureBezoar formationImpaired absorption of co-administered drugs such as fluoroquinolones, digoxin, and phenytoin
06

Interacting drugs

Sucralfate
07

Biomarkers

Endoscopic evidence of mucosal erosionGastric pH

Beyond the preview

Go deeper on Positively charged proteins in damaged mucosa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Positively charged proteins in damaged mucosa.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call